Research Funding Disparity
The economic argument for increased ME/CFS research funding is not that the disease is underfunded in absolute terms — it is that it is underfunded relative to its burden, in a pattern that distinguishes it from every other chronic disease of comparable severity.
Mirin et al. (2020) compared ME/CFS disease burden (IOM 2015 USD 17–24B estimate, plus DALY-based burden metrics) against NIH research funding (~USD 15M/year) and found a burden-to-funding ratio of approximately 1,000:1 — meaning the disease generates roughly USD 1,000 in economic cost for every USD 1 of NIH research funding (Mirin, Dimmock, and Jason 2020). By comparison, multiple sclerosis (annual cost USD 39,000–68,000/patient, comparable per-patient to ME/CFS) received ~USD 115M/year in NIH funding — a burden:funding ratio of ~30:1 (Simoens 2022). Rheumatoid arthritis (annual cost USD 12,000–21,000/patient) received ~USD 86M/year — ratio ~32:1 (Hsieh et al. 2020). The three-order-of-magnitude gap between ME/CFS and comparably burdensome diseases is the strongest single piece of quantitative evidence for research neglect. (Certainty: 0.65 — Mirin 2020 burden side relies on IOM 2015 modeled estimate; funding figures are public NIH data and verifiable; cross-disease comparators are systematic reviews. The ratio’s magnitude depends on the burden estimate — if IOM overestimated burden by 2x, the ratio is still ~500:1. The qualitative conclusion — ME/CFS is severely underfunded relative to burden — is robust to plausible variation in the burden estimate.)
Consequence: The burden:funding ratio is the chapter’s most politically actionable finding. For an NIH program officer, a congressional staffer, or a research charity allocating funds, the phrase 1,000:1 cost:funding ratio is a single number that captures the structural neglect. The cross-disease comparators (MS, RA) are critical — they establish that the disparity is not explained by inherent difficulties in studying ME/CFS (MS and RA are also complex, chronic, immune-mediated diseases with no cure) but by a systematic underinvestment that predates and is independent of any scientific challenge. Severity applicability: research funding affects all severity levels, but severe/very severe patients — who have the least capacity to participate in advocacy — are the most affected by funding scarcity, because they have the greatest need for treatment discovery and the least ability to travel to the few existing research centers.
The German data reproduce the U.S. funding disparity documented in The Burden-to-Funding Ratio using independent government figures. Federal research spending on Long COVID and ME/CFS averaged roughly EUR 40 million per year over 2020–2025 — equal to 0.06% of the EUR 64.4 billion the two diseases cost Germany in 2025 alone (Daniell et al. 2026). Of the EUR 221 million in federal funding allocated since 2022, only 22% (EUR 50 million) went to biomarkers, diagnostics, and treatments, while 71% (EUR 157 million) went to healthcare-services research such as rehabilitation and psychotherapy — interventions that the report’s authors note do not alter the disease state in PEM-characterized ME/CFS and are therefore unlikely to reduce societal cost (Daniell et al. 2026). The services-versus-biomedical allocation is the same structural pattern analyzed in Healthcare Systems, Policy, and Disability. Germany’s announced National Decade Against Post-infectious Diseases (EUR 500 million over ten years, EUR 50 million per year) begins to address this, and a peer-reviewed health-economic model independently estimates the optimal German ME/CFS research investment at EUR 676 million — roughly one-quarter of total drug-development cost — against EUR 2.6 billion in expected societal value from a single prospective drug (Gandjour 2024). (Certainty: 0.55 — federal funding figures are public German government budget data and verifiable; the 0.06% ratio is arithmetically derived; the biomedical-versus-services split reflects the report’s classification of funding streams; Gandjour 2024 is a peer-reviewed single-author model. Population weight 1.00.)
Consequence: Two large Western economies now show the same three-orders-of-magnitude gap between disease cost and research investment — evidence that the neglect is a structural feature of how post-infectious disease is funded, not a single country’s failure. The 71%-to-services split is the actionable part: it names where the money currently goes (services that do not alter the disease) versus where it is needed (biomedical research that might), giving a concrete reallocation target for the National Decade. Severity applicability: research funding affects all severity levels, but the biomedical-funding deficit falls hardest on severe and very severe patients, who benefit least from rehabilitation services and have the greatest need for disease-modifying treatments.
The burden:funding ratio is a descriptive comparison, not a causal model. It shows disparity but does not answer the policy question: if ME/CFS research funding increased to parity with MS (~USD 115M), what return would that generate? A formal ROI analysis would require: (1) modeling the probability that increased funding yields a disease-modifying treatment within N years, (2) estimating what fraction of the USD 17–24B annual burden such a treatment would eliminate, and (3) discounting future benefits to present value. No such analysis exists for ME/CFS. The Cochrane 2021 systematic review confirmed that zero cost-effectiveness studies exist for any ME/CFS intervention — including research funding itself as an intervention (Cochrane et al. 2021).
Consequence: The burden:funding ratio is persuasive but not probative for a specific funding target. It tells you the present state is unjustified; it does not tell you what funding level would be optimal. In policy contexts, this distinction matters — a cost-effectiveness analyst will ask “what is the marginal return on the next 10 million dollars?” and the current literature cannot answer. This limitation is not a weakness of the case for increased funding; it is a consequence of the same underfunding that the case critiques. (Certainty: 0.75 — confirmed by Cochrane 2021 systematic review (Cochrane et al. 2021); absence of evidence for ROI of ME/CFS research funding is a documented finding from systematic search, not an assumption.) Severity applicability: the ROI gap affects evidence-based funding advocacy across all severity levels.